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Abstract
A 530 nm light emitting diode was coupled to a microfluidic sensor to facilitate photolysis of 
nitrosothiols (i.e., S-nitrosoglutathione, S-nitrosocysteine, and S-nitrosoalbumin) and 
amperometric detection of the resulting nitric oxide (NO). This configuration allowed for 
maximum sensitivity and versatility while limiting potential interference from nitrate 
decomposition caused by ultraviolet light. Compared to similar measurements of total S-
nitrosothiol content in bulk solution, use of the microfluidic platform permitted significantly 
enhanced analytical performance in both phosphate buffered saline and plasma (6–20× 
improvement in sensitivity depending on nitrosothiol type). Additionally, the ability to reduce 
sample volumes from milliliters to microliters provides increased clinical utility. To demonstrate 
its potential for biological analysis, this device was used to measure basal nitrosothiol levels in the 
vasculature of a healthy porcine model.
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Introduction
Nitric oxide (NO), a seemingly ubiquitous endogenous free radical, is intricately involved in 
a number of physiological processes including wound healing,1–4 angiogenesis,5–8 and the 
immune response.9–12 As such, the detection and quantification of NO and its metabolites is 
the subject of intense investigation, especially in biological environments.13–21 S-
nitrosothiols (RSNOs), present in both low molecular weight (e.g., S-nitrosoglutathione and 
S-nitrosocysteine) and macromolecular (e.g., S-nitrosoalbumin) forms in vivo,22–29 are a 
class of metabolites believed to be the primary endogenous reservoirs and transporters of 
NO resulting from the nitrosation of thiols within blood plasma (which contains ~600 μM 
free thiols), cells, and tissues.30 Furthermore, RSNO concentrations have been identified as 
important in a number of disease states, including sepsis, asthma, and tuberculosis.25,31–33 
While some RSNOs have even been employed for clinical applications (e.g., S-nitroso-N-
acetyl-penicillamine as a vasodilator),27,34 further understanding of the formation, 
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decomposition, and circulating concentrations of these species in both healthy and disease 
states is vital as future therapeutic uses emerge.
To date, nearly all RSNO measurement strategies are based on chemiluminescence, 
fluorescence, or electrochemistry.13,18,35–37 These methods rely on the indirect 
quantification of RSNOs via homolytic cleavage of the S—N bond with subsequent NO 
release and detection. Reductive catalytic bond cleavage can be achieved via copper ions or 
other reducing agents (e.g., ascorbate), but requires the addition of external reagents.38–46 
Photolysis is an alternative means of achieving S—N bond cleavage that is easily coupled to 
any detection platform. In such experiments, the frequency of light has been proven to be an 
important parameter. For example, the use of visible over ultraviolet light allows for 
efficient photolysis while avoiding the possibility of overestimation due to the generation of 
NO from nitrate.47–50 Riccio et al. previously reported on the use of visible photolysis and 
amperometric detection for the quantification of RSNOs in both phosphate buffered saline 
(PBS) and blood plasma.51 To achieve adequate limits of detection, this detection scheme 
required deoxygenation of samples to avoid the reaction of NO with oxygen. The 
requirement of large sample volumes (40 mL), further limited the clinical utility of the 
setup.
In contrast, microfluidic devices permit the use of significantly reduced sample volumes, 
improving amenability to clinical analysis.52,53 The smaller sample volume also allows for 
more complete sample irradiation, thus increasing the RSNO to NO conversion efficiency of 
photolysis. Improvements in limits of detection and RSNO conversion to NO using a 
microfluidic platform have the potential for more accurate measurement of biologically 
relevant RSNO concentrations in physiological media (e.g., blood serum or plasma).
Herein, we report the use of a modified microfluidic platform for enhanced visible 
photolysis and amperometric detection of total RSNO concentration. The improved 
analytical performance of this device is demonstrated in both PBS and blood plasma. The 
device was also used to monitor the basal endogenous RSNO levels in healthy swine.
Materials and Methods
(Heptadecafluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane (17FTMS) was purchased from 
Gelest (Morrisville, PA). Methyltrimethoxysilane (MTMOS), (3-
aminopropyl)triethoxysilane (APTES), reduced L-glutathione (GSH), bovine serum albumin 
(BSA), L-cysteine-hydrochloride (Cys), diethylene triamine pentaacetic acid (DTPA), water 
soluble cholesterol, and ferrous stabilized human hemoglobin A0 were purchased from 
Sigma (St. Louis, MO). Nitric oxide gas (99.5% pure) was purchased from Praxair 
(Danbury, CT). Amicon™ Ultra-4 centrifugal filters (30 kDA cutoff) were obtained for 
EMD Milliore (Billerica, MA). Nitrogen and argon gases were purchased from National 
Welders Supply (Raleigh, NC). A Millipore Milli-Q UV Gradient A10 System (Billerica, 
MA) was used to purify distilled water to a final resistivity of 18.2 MΩ·cm and a total 
organic content of <6 ppb. A high-power mounted 530 nm light-emitting diode (LED; 
model M530L2) and driver were purchased from Thorlabs Inc. (Newton, NJ). Other solvents 
and chemicals were analytical-reagent grade and used as received.
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Devices were fabricated as previously described.15 Briefly, 150 nm thick planar platinum 
(Pt) electrodes with a 10 nm titanium seed layer were patterned onto a glass substrate via 
photolithography and evaporative metal deposition. The resulting Pt electrodes were 100 μm 
wide. To impart selectivity to NO, a xerogel membrane was applied to each working 
electrode. Following the deposition of a 1002F-50 photoresist and exposure through a 
chrome mask, the electrode pattern was developed in SU-8 developer (Microchem Corp.; 
Newton, MA) and an adhesion layer of APTES (1% v/v in ethanol) was deposited via three 
passes with a spray coater. The substrate was then rinsed with water and dried in ambient 
conditions overnight. A fluoroalkoxysilane membrane solution was prepared via the acid 
catalyzed hydrolysis and condensation of 17FTMS and MTMOS as reported previously.15,21 
Briefly, 600 μL absolute ethanol, 120 μL MTMOS, 30 μL 17FTMS, 160 μL distilled water, 
and 10 μL 0.5 M HCl were added sequentially to a 1.5 mL microcentrifuge tube with 
vigorous mixing between the addition of each component. This solution was then vortexed 
for 1 h. The sol solution (30 μL) was spread-cast across the working electrodes for 1 min 
using a pipette tip to ensure even coating (~150 nm thickness). The xerogel-coated substrate 
was then dried overnight under ambient conditions to facilitate adequate curing. The 
1002F-50 photoresist was removed by soaking the substrate for 1 h in distilled water.
Reference electrodes were fabricated on separate glass microscope slides by sputtering a 10 
nm Ti adhesion layer followed by a ~1 μm Ag layer in the magnetron sputtering system. To 
form channel walls, two parallel strips of 6.3 mm wide double-sided Kapton® polyimide 
tape (90 μm thick) were applied ~1 mm apart and perpendicular to the Pt electrodes on the 
working electrode substrate. The reference electrode slide was then clamped to the working 
electrode substrate bonded by heating at 100 °C for 5 min. After the ends of the channel 
were sealed, 8 mm diameter inlet/outlet reservoirs were affixed to the device. Prior to using 
the device, the Ag electrode was chemically oxidized by reaction in 50 mM ferric chloride 
for 10 s to create a pseudo-reference/counter electrode. Following this process, the device 
channel was rinsed with distilled water.
Preparation of S-nitrosothiols
Low molecular weight RSNOs were prepared using a previously reported procedure.51,54 
Nitrosation of thiols was achieved by mixing 5 mM GSH or Cys dissolved in 120 mM 
sulfuric acid with an equal volume of 5 mM sodium nitrite in 20 μM EDTA. S-
nitrosoalbumin (AlbSNO) was prepared by mixing a solution of BSA (200 mg mL−1 in 
water) with 1.5 mM sodium nitrite in 0.5 M hydrochloric acid in the dark for 30 min.24 Final 
concentrations of the RSNO solutions (diluted 1:10 in PBS) were determined via their UV 
absorption maxima at 335 nm (ε = 503, 586, and 3869 M−1 cm−1 for S-nitrosocysteine 
(CysNO), S-nitrosoglutathione (GSNO), and AlbSNO, respectively).55 Nitrosothiol 
solutions were shielded from light and stored at 4 °C prior to use to prevent premature 
degradation.
Electrochemical analysis of S-nitrosothiols
The working and reference/counter electrodes of the microfluidic device were connected to 
a CH Instruments 1030A 8-channel potentiostat (Austin, TX). Prior to sample analysis, the 
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device was polarized at +800 mV vs. the Ag/AgCl pseudo-reference/counter electrode for at 
least 1 h in PBS with 500 μM DTPA (required to chelate free copper ion and avoid 
undesirable RSNO degradation). The LED was placed 100 mm above the device and 
focused using an adjustable biconvex lens to tune the focus and resulting spot size of the 
light upon the channel. An LED driver was used to vary light intensity. To calibrate the 
device, a saturated NO standard solution (prepared by purging deaerated PBS with NO gas 
for ~10 min to yield a 1.9 mM solution of NO) was diluted with PBS and introduced into the 
inlet reservoir. Nitrosothiol samples were introduced into the device in an identical manner. 
The light intensity of the LED at the device channel was measured at 530 nm using a 
Newport Model 840-C hand-held optical power meter (Irvine, CA). Plasma was prepared by 
collecting fresh blood into 3 mL EDTA-coated Vacutainer® tubes (Becton, Dickinson and 
Company; Franklin Lakes, NJ) and centrifugation of this sample at 4 °C (1300 ×g for 10 
min). Following introduction of plasma into the device, aliquots of each RSNO were added 
to facilitate calibration. To determine the ability to detect RSNOs added to whole blood, a 
similar calibration was performed where RSNOs were added to blood prior to 
centrifugation, with subsequent analysis of the resulting plasma.
Determination of the effect of cholesterol and hemoglobin on S-nitrosothiol measurement
Ferrous oxyhemoglobin was reconstituted in PBS and diluted to 1, 5, and 10 μM for 
immediate use. A calibration was performed in each hemoglobin sample using stock GSNO 
(up to 20 μM final concentration) to determine sensitivity changes relative to PBS alone. To 
determine the feasibility of Hb removal via centrifugal filtration, 5 μM Hb and 35 μM 
GSNO were added to a PBS sample (2 mL). A small volume of this sample (300 μL) was 
immediately analyzed using the microfluidic device. The remaining sample was placed into 
a centrifugal filter, centrifuged at 4 °C (4500 ×g for 15 min), and then immediately 
analyzed. Cholesterol samples were prepared by adding water-soluble cholesterol (1.5, 2.5, 
and 3.0 mg mL−1) to plasma samples. An aliquot of GSNO stock solution (35 μM final 
concentration) was added to each cholesterol solution and analyzed immediately using the 
microfluidic device.
Determination of basal S-nitrosothiol levels in blood
Arterial blood was collected from Yucatan™ miniature swine (n=4 animals) into 3 mL 
EDTA-coated Vacutainer® tubes. The blood was immediately centrifuged at 4 °C (1300 ×g 
for 10 min) to isolate blood plasma. This sample was subsequently run through the 
microfluidic device. Following sample introduction, the LED was turned on to facilitate 
RSNO decomposition to NO. Samples were also analyzed following centrifugal filtration 
using a 30 kDa cutoff membrane to remove AlbSNO and free hemoglobin. Following the 
collection of plasma, ~2 mL was introduced into the filter apparatus and centrifuged at 4 °C 
(4500 ×g for 15 min).
Results and Discussion
The microfluidic NO sensor utilized herein has been previously characterized with respect to 
blood NO analysis.15 In other works, Riccio et al. established the effectiveness of green 
(500–550 nm) light for photolysis of RSNOs with subsequent amperometric detection of 
Hunter and Schoenfisch Page 4













NO. As such, initial analyses focused on optimizing a light source for incorporation of 
visible photolysis and amperometric detection of RSNOs within the microfluidic device 
platform. A 530 nm high-power LED was chosen as the ideal source due to its small size 
and amenability to tuning position, focus, and light intensity. The LED was positioned 
directly over the microfluidic channel at a distance of 100 mm to ensure complete irradiation 
of the sample prior to reaching the working electrode while also avoiding sample heating 
(Figure 1). The total transit time from the device inlet to the NO selective electrode was ~5 
s.
Optimization of LED configuration
The low molecular weight nitrosothiol GSNO in oxygenated PBS was used to evaluate the 
effect of light intensity and irradiation area/focus. When evaluating intensity, the LED light 
was focused to a 10 mm diameter spot centered on the inlet channel. As indicated in Table 1, 
greater light intensity yielded a linear increase in sensitivity while improving the limit of 
detection (attributed to greater RSNO to NO conversion with the more intense source). 
Representative current traces as a function of light intensity are given in Figure 2. To 
evaluate the effect of irradiating a larger portion of the channel (the channel length from 
inlet to working electrode is ~20 mm), the focus of the light was altered to create a larger 
area of irradiation, centered along the length of the channel. Spot sizes of 5, 10, and 20 mm 
in diameter produced slightly varied output powers of 34, 40, and 27 mW, respectively. 
While a significant difference in sensitivity was observed between the 10 and 20 mm spot 
diameters (22.6 ± 1.6 and 12.3 ± 1.2 pA μM−1), all sensitivities became equal when 
normalized to output power (~0.5 pA μM−1 mW−1), indicating this difference resulted from 
the change in apparent light output instead of variation in irradiation area. The optimized 
configuration was used (focused 10 mm diameter light at 100% intensity) for subsequent 
experiments.
Detection of common low molecular weight and macromolecular nitrosothiols
In addition to GSNO, the utility of this device was evaluated for sensitivity to CysNO and 
AlbSNO in oxygenated PBS (to represent a physiologically relevant system). As indicated in 
Table 2, the device exhibited identical sensitivities for both low molecular weight RSNOs 
(i.e., GSNO and CysNO; 22.6 ± 1.6 and 25.5 ± 1.3 pA μM−1, respectively), an expected 
result due to comparable molar absorptivities at the irradiation wavelength (ε = 17.2 and 
14.9 M−1 cm−1 at 530 nm, respectively). The maximum current signal was obtained after 
only 100 s, with linear response from 1–40 μM, well beyond expected in vivo concentrations 
(Figure S-1 and S-2, Supporting Information). Based on the oxidation current measured 
from dilutions of a saturated NO solution, utilizing visible photolysis within the microfluidic 
device configuration allows for a ~40% conversion of RSNO to free NO. Compared to 7–
11% conversion in a 25 mL deoxygenated solution reported by Riccio et al. (using 
chemiluminescence detection),51 this result represents a significant improvement compared 
to utilizing this method in bulk solution. The ability of the device to detect NO from 
nitrosated serum albumin (AlbSNO) was also evaluated, as nitrosated proteins make up the 
majority of RSNO species in vivo.23 Not surprisingly, an ~80% decrease in sensitivity was 
observed compared to low molecular weight RSNOs. The greater stability of AlbSNO 
relative to low molecular weight RSNOs is well known and attributed to the protection of 
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the nitrosocysteine group within a hydrophobic pocket of the protein.22,23,29,56 Of note, 
albumin contains only a single free cysteine residue for nitrosothiol formation despite its 
greater size,23 making its theoretical NO storage/release equivalent to GSNO and CysNO.
After normalizing for differences in irradiation power and electrode surface area, a 6–8× 
improvement was observed for the low molecule weight RSNOs after 1 min irradiation, 
while the sensitivity for AlbSNO was improved by ~20×. In addition, the LOD for each was 
improved by at least 55%. Importantly, the results reported herein were obtained in 
oxygenated PBS. Further performance improvements would be expected in deoxygenated 
solutions. Indeed, a 44% increase in current was noted for a sample of GSNO upon dilution 
in deoxygenated versus oxygenated PBS (data not shown).
Detection in plasma
To fully evaluate the utility of this device for the determination of RSNOs in biologically 
relevant systems, it was important to establish whether measurement in physiological milieu 
(i.e., whole blood and plasma) was possible. Despite the significantly reduced sample cross-
section (~90 μm) and irradiated volume (~450 nL), detection of exogenous RSNOs added to 
whole blood was not possible, likely due to light scattering and/or absorbance by red blood 
cells. Based on complete blood cell counts obtained from these samples, 450 nL of blood 
contains an average of 2 × 106 red blood cells. Nevertheless, measurements of RSNOs in 
oxygenated plasma were possible using the microfluidic device whether plasma was spiked 
with RSNOs or the RSNOs were first added to whole blood with subsequent centrifugation 
to collect plasma. Compared to measurements carried out in PBS, the sensitivities and limits 
of detection in plasma were greatly reduced, with an ~80% decrease in sensitivity for all 
RSNO species evaluated as shown in Table 2. Identical responses were achieved regardless 
of how the RSNO was added to the samples (Figure S-2, Supporting Information). Samples 
that were frozen (−20 °C) and reanalyzed after 24 h exhibited a ~50% decrease in sensitivity 
(data not shown). Based on these sensitivities, limits of detection of 400, 240, and 2660 nM 
were achieved for GSNO, CysNO, and AlbSNO, respectively. This diminished response is 
somewhat expected due to the opacity of plasma relative to PBS, as well as NO scavenging 
and light scattering due to the presence of proteins.57,58 Indeed, the transmittance of 530 nm 
light in blood plasma is decreased by ~26% relative to PBS.
Effect of cholesterol and hemoglobin concentration
Evaluation of NO scavenging and plasma turbidity is important for validating the potential 
clinical utility of the measurement technique. Small amounts of red blood cell hemolysis are 
common during blood centrifugation to plasma.59 Free oxygenated hemoglobin (1, 5, and 10 
μM) was thus added to PBS to determine its effect on the GSNO measurement. As shown in 
Table 3 (calibration data using 1–20 μM GSNO), the lowest free hemoglobin concentration 
(1 μM) did not significantly impact the measurement sensitivity. In contrast, the 5 and 10 
μM free hemoglobin resulted in decreased sensitivity by ~35 and 71%, respectively. This 
result was somewhat anticipated as oxyhemoglobin rapidly scavenges NO.60 Accurate 
measurement of GSNO using this approach might be challenging without knowing the 
extent of hemolysis in a given sample. Fortunately, a simple centrifugal filter of appropriate 
molecular weight cutoff could be utilized to remove free hemoglobin following blood 
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centrifugation and prior to analysis using the microfluidic device. Indeed, full signal 
restoration (a 33% improvement) was achieved following filtering of the sample containing 
5 μM hemoglobin.
Changes in sample turbidity may also influence accurate RSNO measurement by changing 
the efficiency of RSNO photolysis. For example, large lipid concentrations may lead to 
underestimation of RSNO levels due to increased turbidity. We next evaluated the effects of 
blood cholesterol levels on the RSNO measurement. Of note, cholesterol concentrations 
>3.0 mg mL−1 are considered to be high and unhealthy in human patients.61 As shown in 
Table 3, the addition of 3.0 mg mL−1 cholesterol only slightly decreased the device 
sensitivity to RSNO relative to blanks (no additional lipid), while lower concentrations of 
cholesterol had little consequence. Nevertheless, a standard addition measurement could be 
employed to correct for sample turbidity variability between samples.
Measurement of endogenous nitrosothiol content
Despite the decreased sensitivity, this technique was used to determine total endogenous 
RSNO levels in fresh plasma separated from blood obtained from healthy swine, with an 
average of 1.5 ± 1.0 μM determined (n=4 animals), which falls within RSNO concentrations 
determined by numerous other methodologies (up to 9 μM).37,51 Samples were also 
analyzed following centrifugal filtration using a 30 kDa cutoff membrane to remove both 
AlbSNO and free hemoglobin. The subsequently measured RSNO concentrations were 
identical (Figure S-4, Supporting Information), indicating that 1) the RSNO concentration 
measured is due wholly to low molecular weight species (i.e., GSNO and CysNO) and 2) 
free hemoglobin did not plague these measurements (from healthy animals).
Conclusions
The work presented herein represents a significant enhancement in the measurement of 
RSNO in physiological fluids using photolytic cleavage with amperometric detection of NO. 
By utilizing a microfluidic device to reduce the sample cross-section and volume, irradiation 
and resulting RSNO decomposition to NO were increased, thus improving the sensitivity 
and limit of detection for both low molecular weight and protein RSNOs. Additionally, the 
required analysis time was minimal (i.e., <2 min for sample irradiation and detection). While 
detection of RSNOs directly in blood was not realized, analysis of blood plasma was 
feasible with measured RSNO levels in healthy swine falling within previously reported 
ranges.37 Furthermore, the measured response was confirmed to be solely from low 
molecular weight RSNOs. This result signifies that low molecular weight RSNOs may be 
present in blood at significantly greater concentrations than protein RSNOs. Future studies 
should include the analysis of RSNO levels during disease states as well (e.g., sepsis) where 
both NO and RSNO concentrations are expected to rise.33,62–64
Small LED sources can easily be coupled to future device designs, potentially allowing for 
simultaneous measurement of NO and RSNO in one sample. Future device designs should 
allow for on-chip separation of red blood cells from plasma to facilitate facile dual analysis 
of NO and RSNO, reduce sample handling, and prevent problems resulting from hemolysis. 
Light sources with greater intensity may also permit the measurement of RSNO directly in 
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whole blood. Within whole blood, S-nitrosohemoglobin is an especially relevant analyte of 
interest, as NO stored/transported in this form may be of importance to NO generation under 
hypoxic conditions.65–67
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Schematic of microfluidic device setup with LED and lens configuration.
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Effect of light intensity on sensitivity. Representative amperometric responses for CysNO 
(75 μM) detection at 100 (blue dashed-dotted, 40 mW), 75 (purple dotted, 25 mW), 50 (red 
dashed, 6 mW), and 25% (black solid, 2 mW) light intensity at 10-mm irradiation diameter.
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Table 1
Effect of light intensity and irradiation area on S-nitrosoglutathione sensitivity in oxygenated phosphate 
buffered saline. Data represent the mean ± standard deviation (n≥3)
Spot diameter (mm) Apparent power (mW) Sensitivity (pA μM−1) LOD (nM)
5 34 17.6 ± 0.9 80
10
40 22.6 ± 1.6 60
25 11.7 ± 2.4 120
6 5.0 ± 1.7 280
2 2.9 ± 0.1 480
0 0.6 ± 0.0 2500
20 27 12.3 ± 1.2 110
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Table 3
Effect of free hemoglobin (in PBS) and cholesterol (in plasma) concentrations on percent light transmittance 
through sample and sensitivity of GSNO measurement.
Hemoglobin
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